Production (Stage)
Senti Biosciences, Inc.
SNTI
$3.21
-$0.10-3.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 9.28M | 7.77M | 8.66M | 9.15M | 8.78M |
| Gross Profit | -9.28M | -7.77M | -8.66M | -9.15M | -8.78M |
| SG&A Expenses | 5.40M | 6.65M | 4.59M | 2.62M | 6.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -178.00K | -- | -- | -- | -- |
| Total Operating Expenses | 14.51M | 14.42M | 13.25M | 11.77M | 14.84M |
| Operating Income | -14.51M | -14.42M | -13.25M | -11.77M | -14.84M |
| Income Before Tax | -14.11M | -610.00K | -28.87M | -11.20M | -12.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.11M | -610.00K | -28.87M | -11.20M | -12.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.11M | -610.00K | -28.87M | -11.20M | -12.11M |
| EBIT | -14.51M | -14.42M | -13.25M | -11.77M | -14.84M |
| EBITDA | -13.58M | -13.49M | -12.30M | -10.80M | -13.86M |
| EPS Basic | -1.41 | -1.34 | -6.31 | -2.45 | -2.65 |
| Normalized Basic EPS | -0.88 | -0.17 | -1.52 | -1.55 | -1.66 |
| EPS Diluted | -1.41 | -1.34 | -6.31 | -2.45 | -2.65 |
| Normalized Diluted EPS | -0.88 | -0.17 | -1.52 | -1.55 | -1.66 |
| Average Basic Shares Outstanding | 10.01M | 4.66M | 4.58M | 4.57M | 4.57M |
| Average Diluted Shares Outstanding | 10.01M | 4.66M | 4.58M | 4.57M | 4.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |